RE: Angle Plc. Why are the likes of Illumina NOT currently offering DNA sequencing of circulating tumour cells?18 Mar 2024 21:46
Hi Moab, yes, I was aware the paper was by AGL employees, hence my choice of words in my earlier post “….. try this research paper from Angle.” But, you will note that the research (section four) they are quoting from is independent research.
You post that the “literature on the benefits of dual analysis is presently slender, and advantages over single analysis not yet established.” Yes, I agree this is a relatively new approach that AGL are pioneering . I think EC has perhaps got ahead of himself with some of his posts. Where I do agree with EC, is that the analysis of the two DNA’s from a single blood sample is both complementary and provides the best of “both worlds”.
To quote from the article’s conclusion “Liquid biopsies are emerging as a less invasive, less costly, and safer tool that provide faster results and are more suited for longitudinal disease monitoring for cancer care. CTCs and ctDNA are described as cornerstones of liquid biopsy analysis, providing minimally in-vasive, real-time clinical information throughout the patient care pathway. Rapid advances in technology and the affordability of NGS continue to excel, paving the way for a new era of liquid biopsy. The omics revolution is driving the dual analysis of CTCs and ctDNA as complementary sources of genomic and transcriptomic information…….”